FDA is taking in retailers' input on limiting OTC loperamide purchases to curb abuse linked to preventing opioid withdrawal symptoms and in tandem is working with manufacturers to cut package sizes. An anticipated first step is elimination of 200-count packages, the largest size.
The effort is part of FDA's initiative to prevent potentially fatal abuse of the active ingredient in Johnson & Johnson Consumer Inc.'s Imodium A-D and numerous OTC generics, which are...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?